Mirum Pharmaceuticals, Inc.
NASDAQ:MIRMBiotechnology
Healthcare
$95.51 +3.81%
+$3.89 today
- Market cap
- $6.24B
- Beta
- 0.51
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$13.57
52W Low $47.89High $114.99
Volume 0.78M
Average 0.95M
Income Statement
Follow revenue through to earnings.
Revenue
$521.31M
FY 2025 · Annual
+54.7% YoYOperating Income
-$22.14M
FY 2025 · Annual
Net Income
-$23.36M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.14M | 77.06M | 186.37M | 336.89M | 521.31M |
| Cost of Revenue | 1.9M | 12.37M | 47.04M | 81.64M | 100.58M |
| Gross Profit | 17.24M | 64.69M | 139.34M | 255.25M | 420.73M |
| Gross Margin | 90.1% | 83.9% | 74.8% | 75.8% | 80.7% |
| Research & Development | 131.43M | 106.84M | 102.61M | 140.63M | 186.18M |
| Selling, General & Admin | 59.22M | 89.07M | 145.88M | 202.22M | 257.03M |
| Operating Expenses | 190.65M | 195.91M | 248.49M | 342.85M | 443.21M |
| Depreciation & Amortization | 975K | 3.24M | 10.83M | 23.63M | 24.24M |
| EBITDA | (65.39M) | (122.85M) | (136.49M) | (48.97M) | 17.21M |
| EBITDA Margin | -341.7% | -159.4% | -73.2% | -14.5% | 3.3% |
| Operating Income | (173.41M) | (131.22M) | (109.15M) | (87.61M) | (22.14M) |
| Operating Margin | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% |
| Interest Income | 366K | 3.86M | 13.74M | 13.79M | 12.73M |
| Interest Expense | 17.59M | 15.98M | 15.11M | 14.31M | 14.39M |
| Other Income / Expenses | 89.46M | (10.85M) | (53.27M) | 694K | 709K |
| Income Before Tax | (83.95M) | (142.07M) | (162.42M) | (86.91M) | (21.43M) |
| Pre-Tax Margin | -438.7% | -184.4% | -87.1% | -25.8% | -4.1% |
| Income Tax Expense | 37K | (6.41M) | 991K | 1.03M | 1.94M |
| Net Income | (83.99M) | (135.67M) | (163.42M) | (87.94M) | (23.36M) |
| Net Margin | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
| EPS (Basic) | (2.77) | (4.01) | (4.00) | (1.85) | (0.47) |
| EPS (Diluted) | (2.77) | (4.02) | (4.00) | (1.85) | (0.47) |
| 30.32M | 33.84M | 40.89M | 47.52M | 50.2M | |
| 30.32M | 33.98M | 40.89M | 47.52M | 50.2M |
MIRM Earnings Waterfall · TTM
NASDAQ:MIRM · Revenue to Net Income
Key Ratios
EPS$-14.56
Gross Margin81.6%
Net Margin-133.5%
P/E Ratio41.4
P/S Ratio33.5
Analysis
$618.1M of revenue converted into -$860.2M of net income for the selected period. Gross margin is 81.6% and net margin is -133.5%, showing how much revenue survives after costs and taxes. EPS is $-14.56, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 |
How much revenue does MIRM generate?
Mirum Pharmaceuticals, Inc. (MIRM) reported $521.31M of revenue in fiscal 2025.
Is MIRM profitable?
Mirum Pharmaceuticals, Inc. (MIRM) reported -$23.36M of net income, with a net margin of -4.5%.
Continue the stock analysis
Jump to another research area for this company.